Results 1 to 10 of about 344,680 (247)

Multiple myeloma [PDF]

Cancer Imaging, 2004
Advances in the imaging and treatment of multiple myeloma have occurred over the past decade. This article summarises the current status and highlights how an understanding of both is necessary for optimum management.
S. Vincent Rajkumar, Robert A. Kyle
  +14 more sources

Multiple Myeloma [PDF]

New England Journal of Medicine, 2011
Multiple myeloma (MM) is a B cell neoplasm of the bone marrow with a complex array of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and compromised immune function. It accounts for 10%–15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow.
PALUMBO, Antonio, Anderson K.
  +9 more sources

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma

Cells, 2022
Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients.
Megan Johnstone, Delaney Vinaixa, Marcello Turi, Eugenio Morelli, Kenneth Carl Anderson, Annamaria Gulla   +5 more
doaj   +1 more source

Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma

Frontiers in Oncology, 2022
AimsTo evaluate abnormal metabolites related to treatment response and prognosis of multiple myeloma (MM) patients through ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS).MethodsForty-six symptomatic MM patients were included ...
Yujun Wei, Jinying Wang, Fei Chen, Xin Li, Jiajia Zhang, Man Shen, Ran Tang, Zhongxia Huang   +7 more
doaj   +1 more source

γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

Blood Cancer Journal, 2022
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs).
Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai   +13 more
doaj   +1 more source

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study

Cancer Medicine, 2022
Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use.
Man Shen, Jiajia Zhang, Ran Tang, Yuhao Wang, Xiaokai Zhan, Sibin Fan, Zhongxia Huang, Yuping Zhong, Xin Li   +8 more
doaj   +1 more source

MRI in multiple myeloma : a pictorial review of diagnostic and post-treatment findings [PDF]

, 2016
Magnetic resonance imaging (MRI) is increasingly being used in the diagnostic work-up of patients with multiple myeloma. Since 2014, MRI findings are included in the new diagnostic criteria proposed by the International Myeloma Working Group.
A Baur, A Baur-Melnyk, A Stabler, AR Padhani, AR Padhani, AR Padhani, AR Padhani, B Turkbey, BC Vande Berg, C Hayes, C Jakob, C Lavini, C Lin, C Messiou, C Nanni, CM Zechmann, D Smith, DM Koh, E Mena, F Alyas, FE Lecouvet, G Pratt, GP Schmidt, HE Daldrup-Link, J Caers, J Hillengass, J Hillengass, J Hillengass, JC Dutoit, JC Dutoit, JC Dutoit, JR Silva Jr, KL Verstraete, KL Verstraete, LA Moulopoulos, LM Shah, M Fenchel, M Horger, M Merz, MA Dimopoulos, MM Khoo, P Bannas, R Garcia-Figueiras, RA Kyle, S Nosas-Garcia, SL Giles, SV Rajkumar, SV Rajkumar, T Derlin, T Derlin, TM Moehler, Y Zha   +51 more
core   +2 more sources

Multiple myeloma

HemaSphere, 2018
The clinical, biochemical and immunochemical features of 52 patients suffering from multiple myelomatosis are reported. Three major criteria were used to establish the diagnosis: serum and urine protein chemistry, bone marrow morphology and the radiological appearances of bone.
Bernard, DB, Lynch, SR, Bothwell, TH, Bezwoda, WR, Stevens, K, Shulman, G   +5 more
openaire   +7 more sources

Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation

Blood Cancer Journal, 2021
MYC upregulation is associated with multidrug refractory disease in patients with multiple myeloma (MM). We, isolated patient-derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells.
Tomoaki Mori, Rakesh Verma, Rie Nakamoto-Matsubara, Ka Tat Siu, Cristina Panaroni, Keertik S. Fulzele, Kenta Mukaihara, Chukwuamaka Onyewadume, Allison Maebius, Hiroki Kato, Lai Ping Wong, Ruslan I. Sadreyev, David T. Scadden, Noopur S. Raje   +13 more
doaj   +1 more source

Multiple myeloma

Annals of Oncology, 2010
Multiple myeloma (MM) is the second most common hematological malignancy, with an incidence of 6/100,000 in Europe. Interactions between myeloma cells and the microenvironment are essential for MM cell survival. Better knowledge of disease biology has led to the introduction of novel agents for the management of myeloma patients.
Dimopoulos, M.A., Terpos, E.
  +6 more sources